Stamp, Lisa KFrampton, ChrisStewart, SarahPetrie, Keith JEdwards, N LawrenceGaffo, AngeloDalbeth, Nicola2025-06-172025-06-172025-01-02Arthritis Care and Research, ISSN: 2151-464X (Print); 2151-4658 (Online), Wiley, 77(6), 727-731. doi: 10.1002/acr.254942151-464X2151-4658http://hdl.handle.net/10292/19333OBJECTIVE: Gout flares are the most important clinical feature of the disease. A hypothetical maximum flare occurrence in the preceding six-months has been suggested to be no flares for a patient acceptable symptom state (PASS) and only one flare for low disease activity (LDA). The aim of this analysis was to determine the relationship between gout flare states (PASS, LDA, and not in LDA or PASS (non-LDA/PASS)) and patient reported outcomes. METHODS: Post hoc analyses of variance were undertaken using data from a 12-month RCT involving 179 people with gout which compared low-dose colchicine to placebo for the first six months while starting allopurinol, with a further 6-month follow-up. Self-reported gout flares were collected monthly. HAQ and EQ-5D-3L were completed 3-monthly and the gout-specific brief illness perception questionnaire was collected at months 0, 6, and 12. RESULTS: In the final six months of the study 68 (38%) participants were classified as being in PASS, 34 (19%) as in LDA, and 77 (43%) as non-LDA/PASS. There was no association between gout flare states and EQ-5D-3L or HAQ. There was a statistically significant association between 3/8 eight BIPQ items, with increasing consequences, identity and concern scores across the three states of PASS, LDA, and non-LDA/PASS. CONCLUSION: The majority of people were able to achieve gout flare PASS or LDA in the second six months after commencing allopurinol. As flare burden increases, so does the impact of gout on the patient. These findings highlight the importance of flare prevention in the management of gout.© 2025 The Author(s). Arthritis Care & Research published by Wiley Periodicals LLC on behalf of American College of Rheumatology.This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.https://creativecommons.org/licenses/by/4.0/4203 Health Services and Systems42 Health SciencesClinical Trials and Supportive ActivitiesClinical ResearchHealth Disparities3 Good Health and Well Being1103 Clinical Sciences1117 Public Health and Health Services1701 Psychology3202 Clinical sciences4201 Allied health and rehabilitation scienceAllopurinolGoutPatient Reported Outcome MeasuresGout SuppressantsMaleFemaleMiddle AgedSymptom Flare UpAgedTreatment OutcomeColchicineAdultDouble-Blind MethodHumansGoutColchicineAllopurinolGout SuppressantsTreatment OutcomeDouble-Blind MethodAdultAgedMiddle AgedFemaleMaleSymptom Flare UpPatient Reported Outcome MeasuresHumansAllopurinolJournal ArticleOpenAccess10.1002/acr.25494